Skip to main content
Caplight Logo









Treme Bio

Treme Bio

Private
Atlanta, GeorgiaHealthcare & Life Scienceshttps://tremebio.com/

Last Round

Series B

Extension

Jan 27, 2026

Total Funding Raised

$219M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Treme Bio is a biotechnology company developing ProLymphNano, a patented drug delivery technology that focuses on the lymphatic system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

drug delivery platformlymphatic targetingnanoparticle drug deliverydrug delivery technologynanomedicinetargeted drug deliverybiotech licensingsustained releasedrug formulationpayload deliverybiodegradable nanoparticles

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Treme Bio Comparables

Compare Treme Bio with similar companies based on industry and business-model similarity.

Treme Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Evoq Therapeutics
74%
Ropirio Therapeutics
69%
Elicio Therapeutics
69%

Treme Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJan 27, 2026
Series BNov 13, 2024
Series A ExtensionMar 8, 2022
Series AJun 22, 2021

Treme Bio Investors

Notable investors and investment history

Treme Bio investors
InvestorRounds
Janus Henderson GroupSeries B Extension
Agent CapitalSeries B
Balyasny Asset Management L.P.Series B Extension
SV Health InvestorsSeries B Extension, Series A, Series A Extension, Series B
Alexandria Venture InvestmentsSeries B Extension, Series A, Series A Extension, Series B
Delos Capital PartnersSeries B Extension, Series B
Polaris PartnersSeries B Extension, Series B, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 27, 2026

    $50M raised from Alexandria Venture Investments and others.

  • Nov 13, 2024

    $84M round led by Delos Capital Partners.

Treme Bio Filings

Explore SEC and related filing metadata, where available.

Treme Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Treme Bio's valuation, stock price, and market status.

Is Treme Bio a public or private company?

Treme Bio is a private company.

What is the current stock price of Treme Bio?

Treme Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Treme Bio worth (valuation)?

Valuation information for Treme Bio is not publicly available.

Can I buy Treme Bio stock?

Treme Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Treme Bio's last funding round?

Funding round information for Treme Bio is not publicly available.

Who are the main investors in Treme Bio?

Investor information for Treme Bio is not publicly disclosed.

Will Treme Bio IPO soon?

No public IPO plans have been announced for Treme Bio.

How can I track Treme Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Treme Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAtlanta, Georgia
Year Founded2026
Last FundingJan 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?